IIM
BIO icon

Intact Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Intact Investment Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,100
Closed -$380K – 264
2024
Q1 		$380K Buy
+1,100
New +$362K 0.02% 240
2023
Q3 		– Sell
-300
Closed -$114K – 256
2023
Q2 		$114K Sell
300
-400
-57% -$163K ﹤0.01% 250
2023
Q1 		$335K Buy
+700
New +$328K 0.01% 237

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Intact Investment Management's BIO Position: Q2 2024 in Review

Intact Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 1,100 shares — an estimated $380K sold.

Intact Investment Management first reported a position in BIO in Q1 2023 and held it in 3 quarters. The position peaked at $380K in Q1 2024. 439 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

  • Intact Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
  • Intact Investment Management sold 1,100 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $380K.
  • Intact Investment Management first reported a position in Bio-Rad Laboratories Class A in Q1 2023 and held it in 3 quarters.
  • Intact Investment Management's Bio-Rad Laboratories Class A position peaked at $380K in Q1 2024.
  • 439 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Intact Investment Management's 13F filing for Q2 2024, filed 30 Jul 2024.